Impact of Perioperative Anesthetic Management on Renal Cancer Progression.

M.D. Anderson Cancer Center

Overview

The relationship between perioperative drugs, including preoperative medications, anesthetics, and analgesics, and postoperative outcomes in cancer patients is a complex and evolving field of study. Understanding how those medications might impact outcomes such as pain, acute kidney injury, and recurrence is crucial for optimizing perioperative care in renal cancer patients.

This retrospective study will investigate the association of perioperative drugs on short and long-term postoperative outcomes in patients undergoing kidney surgeries for renal cell carcinoma.

Study Type

OBSERVATIONAL

Conditions

Perioperative Anesthetic Renal Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Adult Participants (18 years of age or older) 2. Participants having radical or partial nephrectomies with curative intent. Exclusion Criteria: 1. Patients with distant metastatic disease and those with multiple (more than 1) primary tumors at the time of the nephrectomy 2. Biopsies 3. Participants who had radiofrequency or microwave ablations.

Locations (1)

MD Anderson Cancer Center

Houston, Texas, United States

Outcomes

Primary Outcomes

Postoperative complications

Time frame: 72 hours and 30 days postoperatively

Secondary Outcomes

Overall survival

The length of time from surgery to last follow-up alive or death.

Time frame: Recurrence-free survival:The length of time from surgery to last seen without recurrence or with recurrent disease.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.